DynPort Vaccine Company LLC Enters Phase I Anthrax Vaccine Clinical Trial
DynPort Vaccine Company Trial to Be Conducted at The Walter Reed Army Institute of Research/Henry M. Jackson Foundation
Tuesday October 15, 8:05 am ET
RESTON, Va., Oct. 15 /PRNewswire/ -- DynPort Vaccine Company LLC (DVC), a leading vaccine development company focused on biodefense vaccines, announced today that it will enter into a Phase I clinical trial consisting of approximately 70 volunteers for a new, injectable recombinant anthrax vaccine. The vaccine consists of a highly purified protein, protective antigen. Using recombinant technology and advanced production processes acquired from AVANT Immunotherapeutics, Inc., of Needham, Massachusetts (Nasdaq: AVAN - News), DVC hopes this vaccine will offer a safe, effective product to support the country's need for a new-generation anthrax vaccine.
The Phase I trial will be conducted at the Walter Reed Army Institute of Research (WRAIR) in conjunction with the Henry M. Jackson Foundation (HMJF). The study will evaluate tolerability, safety and immunogenicity of DVC's new vaccine being developed for the Department of Defense through the Joint Vaccine Acquisition Program. In pre-clinical studies, the vaccine, which is produced using modern protein production and purification technologies, was found to be safe and efficacious.
"Protection against potential future biological attacks continues to be a key concern of our nation's leaders," said DVC President Terry Irgens. "At DVC, our mission remains to develop and manufacture biodefense vaccines to protect our country's operating forces and citizens. We do this by applying new technologies and our established expertise to the development of new generation anthrax and other vaccines."
Robert Hopkins, M.D., M.P.H. & T.M., DVC's director of clinical research, supervises the clinical development for all DVC vaccine clinical trials, including a new vaccine for smallpox. Merlin L. Robb, M.D. is serving as the principal investigator for the anthrax clinical trial at WRAIR/HMJF.
DVC is a joint venture between DynCorp of Reston, Va., and Porton International Inc. DVC is the prime systems contractor of Joint Vaccine Acquisition Program and is responsible for developing, licensing and supplying biodefense vaccines required for the Department of Defense.
Visit DVC on the World Wide Web at dyncorp.com . Visit DynCorp on the World Wide Web at dyncorp.com . DynCorp news releases are available through Company News on-call at prnewswire.com .
Make Your Opinion Count - Click Here |
